Literature DB >> 11494133

p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner.

J Zhu1, S Nozell, J Wang, J Jiang, W Zhou, X Chen.   

Abstract

p73, a member of the p53 family, can induce apoptosis in cancer cells. Since p53-mediated apoptosis can be augmented by various cancer chemotherapeutic agents, it has been hypothesized that the status of the endogenous p53 gene in cancer cells is a key determinant in the outcome of cancer therapy. To determine whether p73 can sensitize cancer cells to apoptosis by DNA damage agents, several MCF7 adenocarcinoma cell lines that inducibly express p73 or p53 under a tetracycline-regulated promoter were generated. We found that at relevant physiological levels, p73, but not p53, is capable of sensitizing MCF7 cells to apoptosis induced by chemotherapeutic agents. In addition, we found that p73 can cooperate with the DNA damaging agent camptothecin to activate the initiator caspase 2. Furthermore, we found that p73 can cooperate with DNA damaging agents or p53 to induce some p53 target genes and activate their promoters. In contrast, in MCF7E6 cells that ectopically express the human papillomavirus E6 oncogene and are functionally p53-null, the ability of p73 to sensitize cells to apoptosis is abrogated. Taken together, these results suggest that a functional interaction between p53 and p73 in MCF7 cells leads to enhanced induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494133     DOI: 10.1038/sj.onc.1204516

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  The C terminus of p53 family proteins is a cell fate determinant.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 2.  Senescence regulation by the p53 protein family.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  Methods Mol Biol       Date:  2013

3.  Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.

Authors:  Youshan Zhao; Chengming Fei; Xi Zhang; Yao Zhang; Juan Guo; Shucheng Gu; Xiao Li; Chunkang Chang
Journal:  Tumour Biol       Date:  2012-09-28

4.  The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.

Authors:  Yong-Sam Jung; Yingjuan Qian; Xinbin Chen
Journal:  J Biol Chem       Date:  2011-08-18       Impact factor: 5.157

5.  CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis.

Authors:  David M Tidd; Caroline M Broughton; Richard E Clark
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

6.  Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.

Authors:  G P Feeney; R J Errington; M Wiltshire; N Marquez; S C Chappell; P J Smith
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

7.  Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways.

Authors:  Ernest K Boamah; David E White; Kathryn E Talbott; Nicoleta C Arva; Daniel Berman; Maria Tomasz; Jill Bargonetti
Journal:  ACS Chem Biol       Date:  2007-05-25       Impact factor: 5.100

8.  α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73.

Authors:  Richa Tiwary; Weiping Yu; Bob G Sanders; Kimberly Kline
Journal:  Breast Cancer Res       Date:  2011-01-07       Impact factor: 6.466

9.  TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.

Authors:  Pingde Zhang; Stephanie Si Liu; Hextan Yuen Sheung Ngan
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

10.  DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.

Authors:  Alex I Zaika; Neda Slade; Susan H Erster; Christine Sansome; Troy W Joseph; Michael Pearl; Eva Chalas; Ute M Moll
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.